secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001213900-25-107873
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics Q3 net loss $13.3M; cash runway into mid-2027; key trial data readouts on track
--------------------------------------------------------------------------------

- Net loss of $13.3M ($0.31 per share) vs $11.2M ($0.50 per share) in Q3 2024.
- Cash, equivalents and investments $133.6M as of Sept 30, expected to fund operations into mid-2027.
- R&D expenses $9.6M, up $1.5M YoY driven by THRIVE-3 startup costs.
- ADVANCED-2 interim data from ~25 BCG-Unresponsive NMIBC patients expected 1Q 2026.
- STARBORN-1 interim update in pediatric LMs expected 4Q 2025; THRIVE-3 first patient dosing by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/0001213900-25-107873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea0263183-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-107873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer